Oncomine Dx Express Test
FDA-approved rapid targeted NGS tumor profiling and companion diagnostic test.
- Developer
- Thermo Fisher Scientific
- Intended use
- Other
- Cancer scope
- Not reported
- Specimen
- FFPE tumor tissue
- Molecular modality
- DNA mutation, RNA
- Current version
- Oncomine Dx Express Test P240040 current FDA configuration (2026)
- Evidence context
- 0 structured studies · 0 indexed performance results · 2 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.